Bluebird Bio, Inc.
BLUEUnlisted companyBluebird Bio, Inc. in brief
Bluebird Bio, Inc. is an unlisted company in the Biotechnology industry, based in Somerville, Massachusetts, USA. It was founded in 1992. In the year to December 2024 it had sales of $84 M and a net loss of $241 M. It employs about 518 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Bluebird Bio, Inc.
Genetix Biotherapeutics (previously bluebird bio, Inc.) based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company is owned by investment funds managed by The Carlyle Group and SK Capital Partners.
One of the company's approved drugs is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Bluebird Bio, Inc. timeline
- 1992
- 🏁Founded
- 2004
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed bluebird bio, Inc.Formerly Genetix Pharmaceuticals Inc.
- 2013
- 🔔· approximateInitial public offering on Nasdaq as BLUE
- 2024
- 💰Record revenue of $84 millionFY2024, the highest of the 6 years on record.
Events of Bluebird Bio, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Bluebird Bio, Inc.
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 2 June 2025 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #904 (Jan 2020) · #1,389 (Jan 2021) · #2,938 (Jan 2022) · #2,447 (Dec 2022) · #2,850 (Jul 2023) · #2,994 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -192.4%
- Operating margin
- -322.7%
- Return on equity
- —
- Liabilities / assets
- 106.9%
- Revenue growth
- +184.1%
- R&D / revenue
- 112.5%
- Revenue per employee
- $162 K
- Profit per employee
- $-465 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $84M | +184.1% | $-270M | $-241M | -287.2% |
| Dec 2023 | $30M | +719.4% | $-244M | $-212M | -718.3% |
| Dec 2022 | $4M | -1.6% | $-250M | $-230M | -6398.3% |
| Dec 2021 | $4M | — | $-591M | $-819M | -22387.4% |
| Dec 2020 | — | — | $-559M | $-619M | — |
| Dec 2019 | $45M | -18.2% | $-563M | $-790M | -1767.7% |
| Dec 2018 | $55M | +54.1% | $-572M | $-556M | -1018.0% |
| Dec 2017 | $35M | — | $-332M | $-336M | -947.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-260M | $3M | $-263M | $-24.84 | — |
| Dec 2023 | $-235M | $4M | $-239M | $-38.59 | — |
| Dec 2022 | $-316M | $8M | $-324M | $-2.93 | — |
| Dec 2021 | $-636M | $15M | $-650M | $-11.89 | — |
| Dec 2020 | $-470M | $29M | $-499M | $-9.95 | — |
| Dec 2019 | $-564M | $71M | $-635M | $-14.31 | — |
| Dec 2018 | $-413M | $56M | $-469M | $-10.68 | — |
| Dec 2017 | $-281M | $62M | $-343M | $-7.71 | — |
Quarterly results
Latest quarter to Mar 2025: revenue $39M (+108.5% on a year earlier), net income $-29M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.
SEC filings
- Jun 2, 20258-KCurrent reportMaterial agreement · Acquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- May 14, 202510-QQuarterly report · period to Mar 2025
- May 14, 20258-KCurrent reportMaterial agreement · Other events
- Mar 28, 20258-KCurrent reportOther events
- Mar 27, 202510-KAnnual report · period to Dec 2024
- Feb 21, 20258-KCurrent reportMaterial agreement · Other events
- Feb 20, 20258-KCurrent reportAgreement ended
- Dec 13, 20248-KCurrent reportBylaws amended
- Dec 4, 20248-KCurrent reportShareholder vote · Other events
- Nov 14, 202410-QQuarterly report · period to Sep 2024
- Nov 14, 20248-KCurrent reportResults of operations
- Nov 6, 20248-KCurrent reportDirectors or officers changed · Shareholder vote
Official filings of Bluebird Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $84 M
- Operating income
- $-270 M
- Net income
- $-241 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $460 M
- Total liabilities
- $492 M
- Total equity
- $-32 M
As of December-2024
Insider trading at Bluebird Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | O. James SterlingChief Financial Officer | Disposal to the company | -5,000 | — | — | 0 | Form 4 |
| filed | Michael CloonanDirector | Disposal to the company | -1,867 | — | — | 0 | Form 4 |
| filed | Richard A. ColvinChief Medical Officer | Disposal to the company | -4,166 | — | — | 0 | Form 4 |
| filed | Najoh Tita-ReidDirector | Disposal to the company | -1,245 | — | — | 0 | Form 4 |
| filed | O. James SterlingChief Financial Officer | Grant or award | +2,500 | — | — | 2,500 | Form 4 |
| filed | Andrew ObenshainPresident and CEO, Director | Disposal to the company | -9,300 | — | — | 0 | Form 4 |
| filed | Elisabeth LeidermanDirector | Disposal to the company | -1,245 | — | — | 0 | Form 4 |
| filed | Mark VachonDirector | Disposal to the company | -1,245 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Bluebird Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Bluebird Bio, Inc. scorecard#
Passes 5 of the 12 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 4). Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 5
- ✓Revenue grew in the newest year184.1%Revenue up 184.1% in fiscal 2024.
- ✓Revenue up more than 5% a year over three years184.0%184.0% a year over the three years to fiscal 2024.
- ✓Faster growth over three years than its peers' median184.0%184.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-24.84 vs -38.59Diluted EPS -24.84 in fiscal 2024 against -38.59 the year before (report's currency).
- ✓Net income higher than five years earlier-$241 M-$241 M in fiscal 2024 against -$790 M in 2019.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$241 MNet income -$241 M in fiscal 2024.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
- ✗Operating margin above its peers' median-322.7%-322.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-322.7%-322.7% in fiscal 2024 against -16145.1% in 2021.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.48 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year76.5%Diluted shares up 76.5% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Bluebird Bio, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -322.7% | -60.5% | |
| Net margin | -287.2% | -68.9% | |
| Revenue growth, 3 years a year | 184.0% | 12.9% | |
| Revenue growth | 184.1% | 15.8% | |
| Free cash flow margin | -313.4% | -61.5% |
2of 8on the Piotroski tests of financial strength
- Net loss of $241 million, the 14th loss-making year in a row.
- Free cash flow was negative: -$263 million.
- The share count rose 76.5% in the year.
- Shareholders' equity is negative: -$32 million.
Bluebird Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 84+184%100% | 29+720%100% | 3.6−1.8%100% | 3.7—100% | 0r251−100%— | 45−18.1%100% | 55+54.1%100% | 35+476%100% | 6.2−56.3%100% | 14—100% | |
| Cost of revenue | 89+167%107% | 34+233%114% | 10—280% | — | 5.4+81.2%— | 3.0+236%6.7% | 0.9−42.0%1.6% | 1.5—4.3% | — | — | |
| Gross profit | −5.6—−6.6% | −4.0—−13.7% | −6.5—−180% | — | — | — | — | — | — | — | |
| Research and development | 94−43.8%112% | 168−16.4%568% | 200r241−37.4%5572% | 320+0.2%8737% | 319r588−2.4%— | 327r582−27.1%732% | 449+64.3%822% | 273+33.3%771% | 205+52.8%3327% | 134—952% | |
| Selling, general and administrative | 168+1.4%200% | 166+17.9%561% | 140r137−33.2%3901% | 210−12.5%5734% | 240r287+1.7%— | 236r271+35.4%528% | 174+86.1%319% | 94—264% | — | — | |
| General and administrative | — | — | — | — | — | — | 174+86.1%319% | 94+43.7%264% | 65+40.9%1058% | 46—328% | |
| Operating expenses | — | — | — | — | — | — | 627+70.5%1148% | 368+34.2%1038% | 274+49.6%4451% | 183—1301% | |
| Total costs and expenses | 265−20.5%316% | 333−3.6%1129% | 346r393−41.9%9611% | 595+6.3%16236% | 559r874−0.7%— | 563r860−10.2%1260% | 627+70.5%1148% | 368—1038% | — | — | |
| Operating income | −270—−323% | −244—−828% | −250r−287—−6955% | −591—−16136% | −559r−623—— | −563r−815—−1260% | −572—−1048% | −332—−938% | −268—−4351% | −169—−1201% | |
| Interest and finance income | 8.2−16.7%9.8% | 9.9+856%33.5% | 1.0—28.7% | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 23+38.1%26.9% | 16+159%55.4% | 6.3—176% | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 44+14.1%52.7% | 39+53.3%131% | 25r20−8.7%702% | 28—755% | −6.9r−6.5—— | −10.0r−10−609%−22.3% | 2.0—3.6% | −1.3—−3.6% | −0.1r3.7−103%−1.2% | 2.3—16.4% | |
| Income before tax | — | — | −266—−7408% | −562—−15357% | −560r−618—— | −556r−790—−1244% | −555—−1018% | −335—−947% | −264—−4291% | −167—−1184% | |
| Income tax | 0.1—0.1% | −0.1−208%−0.4% | 0.1−54.7%3.3% | 0.3−62.4%7.0% | 0.7—— | −0.5−391%−1.2% | 0.2−11.0%0.3% | 0.2—0.6% | −0.6−1120%−9.9% | 0.1—0.4% | |
| Income from continuing operations | −241—−287% | −212—−718% | −267—−7411% | −563—−15364% | −561—— | −555—−1242% | — | — | — | — | |
| Income from discontinued operations | — | — | 0—0.0% | −257—−7011% | −58—— | −235—−525% | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | −790—−1767% | −556—−1018% | −336—−947% | −264—−4281% | — | |
| Net income attributable to shareholders | −241—−287% | −212—−718% | −230r−267—−6404% | −819—−22375% | −619—— | −790—−1767% | −556—−1018% | −336—−947% | −264—−4281% | −167—−1185% | |
| Earnings per share, basic | -24.84—— | -38.59r-1.93—— | -2.93r-3.39—— | -11.89—— | -9.95—— | -14.31—— | -10.68—— | -7.71—— | -7.07—— | -4.81—— | |
| Earnings per share, diluted | -24.84—— | -38.59r-1.93—— | -2.93r-3.39—— | -11.89—— | -9.95—— | -14.31—— | -10.68—— | -7.71—— | -7.07—— | -4.81—— | |
| Shares, weighted average (basic) | 9.7+76.5%— | 5.5r110−93.0%— | 79+14.0%— | 69+10.8%— | 62—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 9.7+76.5%— | 5.5r110−93.0%— | 79+14.0%— | 69+10.8%— | 62+12.7%— | 55+6.1%— | 52+19.5%— | 44+16.8%— | 37+7.5%— | 35—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 62−71.9%13.5% | 222+96.2%35.8% | 113−29.9%19.8% | 161−38.2%27.1% | 261r318−20.3%14.6% | 327−18.7%18.9% | 403−46.9%17.9% | 759+172%39.9% | 279+69.8%24.9% | 164—16.4% | |
| Short-term investments | — | 0−100%0.0% | 67−51.3%11.8% | 138−67.0%23.3% | 420r834−46.2%23.6% | 779−20.7%45.1% | 983+84.9%43.8% | 532+24.9%28.0% | 425+20.3%38.1% | 354—35.3% | |
| Receivables | — | — | 0—0.0% | — | — | — | — | 4.6—0.2% | — | — | |
| Inventory | 65+184%14.1% | 23—3.7% | 0—0.0% | 0−100%0.0% | 11—0.6% | — | — | — | — | — | |
| Other current assets | — | — | 11—1.9% | — | — | — | — | — | 3.1r20−48.7%0.3% | 6.0—0.6% | |
| Current assets | 155−45.1%33.6% | 282+38.4%45.5% | 204r199−39.5%35.7% | 337−72.3%56.7% | 1,216+5.5%68.2% | 1,152−18.8%66.7% | 1,419+7.3%63.3% | 1,323+82.6%69.6% | 724+38.2%64.8% | 524—52.3% | |
| Property, plant and equipment | 61−7.7%13.2% | 66+604%10.6% | 9.4−3.5%1.6% | 9.7−44.1%1.6% | 17r163−88.5%1.0% | 151−38.7%8.8% | 247+23.6%11.0% | 200+27.2%10.5% | 157+90.0%14.0% | 83—8.2% | |
| Right-of-use (leased) assets | 177−12.0%38.4% | 201−12.9%32.5% | 231r282+152%40.5% | 92+35.5%15.4% | 68r184−63.7%3.8% | 186—10.8% | — | — | — | — | |
| Goodwill | 5.60.0%1.2% | 5.60.0%0.9% | 5.60.0%1.0% | 5.60.0%1.0% | 5.6r13−57.0%0.3% | 130.0%0.8% | 130.0%0.6% | 130.0%0.7% | 130.0%1.2% | 13—1.3% | |
| Other intangible assets | 9.5−8.5%2.1% | 10+114%1.7% | 4.9—0.9% | 0−100%0.0% | 4.4r10−69.3%0.2% | 14+8.8%0.8% | 13−22.2%0.6% | 17−18.2%0.9% | 21−15.4%1.9% | 24—2.4% | |
| Total assets | 460−25.7%100% | 619+8.7%100% | 570r555−4.0%100% | 594−66.7%100% | 1,781+3.1%100% | 1,727−23.0%100% | 2,243+18.0%100% | 1,901+70.0%100% | 1,118+11.6%100% | 1,002—100% | |
| Accounts payable | 34+85.5%7.5% | 18+24.4%3.0% | 15r25−42.6%2.6% | 26+87.4%4.4% | 14r22−67.9%0.8% | 43+141%2.5% | 18+38.5%0.8% | 13−5.8%0.7% | 14+116%1.2% | 6.3—0.6% | |
| Debt due within a year | 72—15.5% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Current liabilities | 321+60.6%69.8% | 200+27.8%32.3% | 157r128+2.3%27.5% | 153−24.9%25.8% | 204−8.9%11.4% | 224+52.7%12.9% | 146+53.2%6.5% | 96+28.3%5.0% | 75+84.6%6.7% | 40—4.0% | |
| Lease liabilities (non-current) | 162−13.5%35.1% | 187−10.7%30.2% | 209r230+215%36.7% | 66+19.3%11.2% | 56r168−67.4%3.1% | 171—9.9% | — | — | — | — | |
| Total liabilities | 492+15.8%107% | 425−2.5%68.6% | 435r359+98.4%76.4% | 220−48.5%37.0% | 426−3.7%23.9% | 442+23.7%25.6% | 358+29.1%16.0% | 277+11.4%14.6% | 249+63.8%22.2% | 152—15.1% | |
| Retained earnings | −4,501—−978% | −4,260—−688% | −4,048r−3,987—−710% | −3,720—−626% | −2,901—−163% | −2,282—−132% | −1,499—−66.8% | −914—−48.1% | −578—−51.7% | −314—−31.3% | |
| Shareholders' equity | −32−116%−6.9% | 195+44.8%31.4% | 134r196−51.4%23.6% | 276r374−79.6%46.5% | 1,355+5.5%76.1% | 1,285−31.8%74.4% | 1,885+16.1%84.0% | 1,623+86.7%85.4% | 869+2.2%77.8% | 850—84.9% | |
| Total liabilities and equity | 460−25.7%100% | 619+8.7%100% | 570r555−4.0%100% | 594−66.7%100% | 1,781+3.1%100% | 1,727−23.0%100% | 2,243+18.0%100% | 1,901+70.0%100% | 1,118+11.6%100% | 1,002—100% | |
| Shares outstanding | 9.7+0.9%— | 9.6r193−88.4%— | 83+16.6%— | 71+7.0%— | 66+20.0%— | 55+1.2%— | 55+10.8%— | 49r49+21.4%— | 41+10.3%— | 37—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 60+115%72.0% | 28+241%94.9% | 8.2r4.9+67.3%228% | 4.9−3.9%134% | 5.1r15+24.4%— | 4.1r13−69.4%9.2% | 13+36.7%24.6% | 9.8+66.1%27.7% | 5.9+59.5%95.9% | 3.7—26.3% | |
| Share-based compensation | 14−29.3%16.4% | 19−44.6%65.9% | 35r35−72.6%976% | 128−18.3%3493% | 157−2.5%— | 161+44.9%360% | 111+108%203% | 53+34.0%150% | 40−3.3%646% | 41—292% | |
| Cash from operating activities | −260—−310% | −235—−797% | −316r−353—−8791% | −636—−17358% | −470—— | −564—−1263% | −413—−757% | −281—−792% | −190—−3081% | −98—−699% | |
| Capital expenditure | −2.6—−3.1% | −4.2—−14.2% | −8.2—−228% | −15—−396% | −29—— | −71—−159% | −56—−102% | −62—−176% | −28r−16—−455% | −7.1—−50.1% | |
| Intangible assets bought | 0—0.0% | −4.9—−16.5% | −5.0—−139% | −8.5—−232% | 0—— | −5.2—−11.7% | 0—0.0% | 0—0.0% | — | — | |
| Cash from investing activities | 3.9−97.5%4.6% | 155−38.1%525% | 250−55.5%6963% | 563—15362% | −84−117%— | 508—1137% | −679—−1245% | −317r−316−572%−894% | 67r63—1090% | −572—−4062% | |
| Debt issued | 71—85.1% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Shares issued | 0−100%0.0% | 248+358%841% | 54—1508% | — | — | 0−100%0.0% | 649−35.5%1190% | 1,007r33+328%2841% | 235r6.9+2224%3817% | 10—71.8% | |
| Cash from financing activities | 87−55.4%104% | 196+1020%665% | 18r54—487% | −94−117%−2566% | 547+2480%— | 21−97.1%47.4% | 738−31.5%1352% | 1,076+346%3038% | 242−50.4%3924% | 487—3457% | |
| Change in cash | −169−245%−201% | 116—394% | −48—−1341% | −167—−4561% | −8.0—— | −35—−79.2% | −355−174%−651% | 479r480+303%1352% | 119r115—1933% | −184—−1304% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 104+128%100% | 39+108%100% | 39*+392%100% | 11−14.4%100% | 16+134%100% | 19+680%100% | 7.8*+12335%100% | 12+17354%100% | 6.9+354%100% | 2.4—100% | 0.1*—100% | 0.1—100% | 1.5—100% | |
| Cost of revenue | 76+40.6%72.9% | 12−52.7%31.6% | 23*+86.9%59.2% | 12+29.1%111% | 29+332%180% | 26+369%139% | 12r9.6*+57957%156% | 9.1r11—73.6% | 6.7r9.6+284%97.2% | 5.5r3.4—231% | 0.0*—33.3% | 0—0.0% | 1.7—115% | |
| Gross profit | 28—27.1% | 26—68.4% | 16*—40.8% | −1.2−136%−11.0% | −13−6755%−79.8% | −7.3—−39.3% | −4.4r−1.8*−10476%−55.6% | 3.3r1.4+4500%26.4% | 0.2r−2.7—2.8% | −3.1r−1.0—−131% | 0.0*—66.7% | 0.1—100% | −0.2—−14.9% | |
| Research and development | 87−42.5%83.6% | 18−29.3%45.8% | 21*−42.3%54.1% | 23−60.4%218% | 25−20.0%156% | 25−39.7%135% | 36r34*+548%461% | 59r45+10.1%472% | 31r42−50.7%456% | 42r46—1747% | 5.6r46*—8849% | 53—74858% | 64—4203% | |
| Selling, general and administrative | 152−12.9%146% | 30−34.7%78.2% | 31*−32.9%81.5% | 40−2.5%375% | 50+24.5%313% | 46+23.7%249% | 47r47*+37.2%598% | 41r41+22.1%329% | 40r40+10.3%587% | 37r37—1574% | 34r31*—54167% | 33—47045% | 37—2416% | |
| Total costs and expenses | 245−24.9%235% | 51−28.5%132% | 52*−37.1%135% | 66−33.8%620% | 76+5.1%469% | 71−9.7%384% | 83r81*+109%1059% | 99r86+17.0%801% | 72r83−32.9%1044% | 79r83—3320% | 40r77*—63016% | 85—119510% | 107r109—7056% | |
| Operating income | −216—−208% | −25—−63.6% | −36*—−94.6% | −67—−631% | −88—−549% | −79−832%−424% | −87r−83*−240%−1114% | −96r−85—−775% | −72r−85—−1041% | 11r8.4—451% | 62r25*—98956% | −85—−119410% | −107—−7070% | |
| Interest and finance income | 6.3−35.0%6.0% | 0.6−76.3%1.6% | 1.2*−39.1%3.0% | 1.6−33.2%15.5% | 2.8+5.9%17.6% | 2.6−8.8%13.9% | 1.9*—24.4% | 2.5—19.8% | 2.7—38.9% | 2.8—119% | — | — | — | |
| Interest expense and finance costs | 23+33.9%21.8% | 5.7+18.3%14.8% | 5.7*+41.8%14.8% | 5.8+34.0%54.4% | 5.5+45.4%33.9% | 4.9+13.7%26.1% | 4.0*—51.3% | 4.3—34.8% | 3.8—54.4% | 4.3—179% | — | — | — | |
| Other non-operating income (expense) | 33−18.0%31.7% | 0.8−93.1%2.0% | 12*+45.3%32.2% | 10−4.1%96.0% | 9.6−2.9%59.8% | 11+16.0%60.1% | 8.5r8.6*−30.0%109% | 11r11+34.8%85.8% | 9.9r9.6+39.9%144% | 9.6r10.0—404% | 12r6.5*—19348% | 7.9—11106% | 7.1—467% | |
| Income before tax | — | — | — | — | — | — | — | −72—−579% | −73—−1059% | 21—892% | 32*—51337% | −77—−107765% | −100—−6592% | |
| Income tax | 0.2—0.2% | 0.1—0.3% | 0.1*—0.3% | −0.1—−0.5% | 0.0—0.1% | 0—0.0% | −0.0*−142%−0.6% | 0−100%0.0% | −0.1—−1.2% | 0—0.0% | 0.1*—175% | 0.0—9.9% | 0—0.0% | |
| Income from continuing operations | — | — | — | — | — | — | — | — | — | — | 32*—51162% | −77—−107775% | −100—−6592% | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −200—−192% | −29—−75.1% | −29*—−74.5% | −61—−573% | −81—−506% | −70−469%−376% | −81r−89*−218%−1032% | −87r−72—−704% | −63r−73—−911% | 19r21—795% | 68r32*—108679% | −77—−107775% | −100—−6592% | |
| Earnings per share, basic | — | -2.98—— | — | -0.31—— | -0.42—— | -7.23r-0.36−4117%— | — | -0.80r-0.66—— | -0.58r-0.67—— | 0.18r0.21—— | — | -0.94—— | -1.36—— | |
| Earnings per share, diluted | — | -2.98—— | — | -0.31—— | -0.42—— | -7.23r-0.36−4117%— | — | -0.80r-0.66—— | -0.58r-0.67—— | 0.18r0.21—— | — | -0.94—— | -1.36—— | |
| Shares, weighted average (basic) | 9.8+1.0%— | 9.8+1.0%— | — | 194+77.7%— | 194+78.2%— | 9.7r193−90.6%— | — | 109+33.8%— | 109+47.3%— | 103—— | — | 82—— | 74—— | |
| Shares, weighted average (diluted) | 9.8+1.0%— | 9.8+1.0%— | — | 194+77.7%— | 194+78.2%— | 9.7r193−90.7%— | — | 109+33.8%— | 109+47.3%— | 103—— | — | 82—— | 74—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 79—26.6% | 79−62.9%26.6% | 62−71.9%13.5% | 71−57.3%15.2% | 144−16.7%26.4% | 212−11.3%33.6% | 222+96.2%35.8% | 165+149%26.9% | 173+112%26.1% | 239—34.5% | 113—19.8% | 66—12.8% | 81—14.2% | |
| Short-term investments | — | — | — | — | — | — | 0−100%0.0% | 8.9−87.8%1.5% | 72+42.0%10.9% | 79—11.4% | 67—11.8% | 73—14.1% | 51—8.9% | |
| Receivables | — | — | — | — | — | — | — | 23—3.7% | — | — | 0—0.0% | — | — | |
| Inventory | 83—28.1% | 83+175%28.1% | 65+184%14.1% | 54+157%11.6% | 33+144%6.1% | 30+696%4.8% | 23—3.7% | 21—3.4% | 14—2.1% | 3.8—0.5% | 0—0.0% | — | — | |
| Other current assets | — | — | — | — | — | — | — | 17—2.8% | — | — | 11—1.9% | — | — | |
| Current assets | 175—59.0% | 175−35.7%59.0% | 155−45.1%33.6% | 151−39.0%32.4% | 204−29.3%37.3% | 272−22.6%43.0% | 282+38.4%45.5% | 247+54.0%40.3% | 288+72.0%43.4% | 351—50.7% | 204r199—35.7% | 160—30.8% | 167—29.2% | |
| Property, plant and equipment | 60—20.4% | 60−33.2%20.4% | 61−7.7%13.2% | 63+528%13.5% | 79+670%14.4% | 90+937%14.3% | 66+604%10.6% | 10.0−13.6%1.6% | 10−29.8%1.5% | 8.7—1.3% | 9.4—1.6% | 12—2.2% | 15—2.5% | |
| Right-of-use (leased) assets | 27—9.1% | 27−86.1%9.1% | 177−12.0%38.4% | 183−37.9%39.4% | 189−37.5%34.7% | 195−27.7%30.9% | 201−12.9%32.5% | 295+2.1%48.0% | 303+3.5%45.7% | 270—39.0% | 231r282—40.5% | 289—55.5% | 293—51.0% | |
| Goodwill | 5.6—1.9% | 5.60.0%1.9% | 5.60.0%1.2% | 5.60.0%1.2% | 5.60.0%1.0% | 5.60.0%0.9% | 5.60.0%0.9% | 5.60.0%0.9% | 5.60.0%0.9% | 5.6—0.8% | 5.6—1.0% | 5.6—1.1% | 5.6—1.0% | |
| Other intangible assets | 9.3—3.1% | 9.3−9.1%3.1% | 9.5−8.5%2.1% | 9.8+82.2%2.1% | 10+82.4%1.8% | 10+82.5%1.6% | 10+114%1.7% | 5.4—0.9% | 5.5—0.8% | 5.6—0.8% | 4.9—0.9% | — | — | |
| Total assets | 296—100% | 296−53.1%100% | 460−25.7%100% | 465−24.2%100% | 545−17.8%100% | 631−8.8%100% | 619+8.7%100% | 614+18.0%100% | 663+15.7%100% | 693—100% | 570r555—100% | 520—100% | 574—100% | |
| Accounts payable | 43—14.4% | 43+120%14.4% | 34+85.5%7.5% | 24+23.3%5.3% | 31+181%5.6% | 19+0.8%3.1% | 18+24.4%3.0% | 20+6.6%3.2% | 11−56.2%1.6% | 19—2.8% | 15r25—2.6% | 19—3.6% | 25—4.3% | |
| Debt due within a year | 72—24.5% | 72+5.0%24.5% | 72—15.5% | 71—15.2% | 70—12.8% | 69—10.9% | 0—0.0% | — | — | — | — | — | — | |
| Current liabilities | 315—106% | 315+7.3%106% | 321+60.6%69.8% | 296+86.2%63.7% | 298+121%54.6% | 294+153%46.5% | 200+27.8%32.3% | 159+25.4%25.9% | 135−9.3%20.4% | 116—16.7% | 157r128—27.5% | 127—24.4% | 149—26.0% | |
| Lease liabilities (non-current) | 24—8.0% | 24−87.0%8.0% | 162−13.5%35.1% | 168−27.6%36.1% | 175−27.1%32.0% | 181−18.6%28.6% | 187−10.7%30.2% | 232−1.0%37.8% | 239−2.1%36.1% | 222—32.0% | 209r230—36.7% | 234—45.1% | 245—42.6% | |
| Total liabilities | 354—120% | 354−29.3%120% | 492+15.8%107% | 471+20.4%101% | 492+31.5%90.3% | 500+48.1%79.2% | 425−2.5%68.6% | 391+8.3%63.7% | 374−4.9%56.4% | 338—48.8% | 435r359—76.4% | 361—69.5% | 393—68.6% | |
| Retained earnings | −4,530—−1531% | −4,530—−1531% | −4,501—−978% | −4,472—−962% | −4,412—−809% | −4,330—−686% | −4,260—−688% | −4,110—−670% | −4,038—−609% | −3,965—−572% | −4,048r−3,987—−710% | −4,019—−773% | −3,942—−687% | |
| Shareholders' equity | −58—−19.6% | −58−144%−19.6% | −32−116%−6.9% | −5.8−104%−1.2% | 53−77.4%9.7% | 131−54.9%20.8% | 195+44.8%31.4% | 153r223−3.8%24.9% | 235r289+30.4%35.4% | 290r355—41.9% | 134r196—23.6% | 159—30.5% | 180—31.4% | |
| Total liabilities and equity | 296—100% | 296−53.1%100% | 460−25.7%100% | 465−24.2%100% | 545−17.8%100% | 631−8.8%100% | 619+8.7%100% | 614+18.0%100% | 663+15.7%100% | 693—100% | 570r555—100% | 520—100% | 574—100% | |
| Shares outstanding | 9.8—— | 9.8−94.9%— | 9.7+0.9%— | 194+81.2%— | 194+82.1%— | 194+82.0%— | 9.6r193−88.4%— | 107+29.1%— | 106+44.7%— | 106—— | 83—— | 83—— | 74—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 61+62.1%59.0% | 16+0.5%40.2% | 14*+56.9%36.1% | 15*+107%145% | 17*+172%103% | 15+151%83.3% | 8.9r25*+92.8%113% | 7.4r1.1*+434%59.8% | 6.1r1.0*+352%88.2% | 6.2r1.1—259% | 4.6r1.3*—7300% | 1.4*—1954% | 1.3*—88.5% | |
| Share-based compensation | 12−34.6%11.2% | 1.7−55.9%4.3% | 4.1*+19.1%10.6% | 2.7−44.5%25.5% | 3.2−44.3%19.9% | 3.8−30.2%20.2% | 3.4*−25.4%43.6% | 4.9−47.2%39.3% | 5.8−35.4%83.5% | 5.4—226% | 4.6r4.7*—7271% | 9.2—12975% | 8.9—586% | |
| Cash from operating activities | −229—−220% | −43—−112% | −50*—−130% | −69*—−650% | −66*—−411% | −75—−402% | −54r−14*—−691% | −50r−62*—−404% | −60r−73*—−864% | −71r−87—−2997% | −20r−56*—−31014% | −77*—−108487% | −94*—−6212% | |
| Capital expenditure | −1.7—−1.6% | −0.9—−2.2% | −0.5*—−1.3% | −0.3*—−2.6% | −0.1*—−0.4% | −1.8—−9.6% | −1.2*—−15.5% | −2.0*—−16.4% | −0.7*—−10.2% | −0.2—−9.7% | −0.1*—−171% | −1.3*—−1780% | −6.0*—−394% | |
| Intangible assets bought | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −4.0*—−51.1% | 0*—0.0% | 0*—0.0% | −0.9—−36.5% | −5.0*—−7937% | 0*—0.0% | 0*—0.0% | |
| Cash from investing activities | 7.7−89.4%7.4% | 3.1—8.0% | 2.5*−34.9%6.4% | 0.5*−99.2%4.4% | 1.6*−76.7%10.1% | −0.7−101%−3.5% | 3.8*−96.3%48.3% | 62*+298%501% | 6.9*−88.7%101% | 82—3450% | 103*—163876% | 16*—21985% | 62*—4060% | |
| Debt issued | 0−100%0.0% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 71—384% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | — | — | |
| Cash from financing activities | 50−66.0%47.7% | 27−58.7%69.0% | 35*−67.2%90.8% | −6.1*—−57.5% | −6.1*—−37.6% | 65−43.9%348% | 107r66*—1360% | −12r−0.0*−126%−95.5% | −14r−0.4*−270%−198% | 115r130—4837% | −37r−0.1*—−58490% | 46*—65246% | 8.0*—529% | |
| Change in cash | −172—−165% | −14—−35.2% | −13*−123%−33.0% | −75*−38339%−703% | −71*—−439% | −11−108%−57.5% | 56*+20.0%718% | 0.2*—1.6% | −66*—−961% | 126—5290% | 47*—74371% | −15*—−21256% | −25*—−1623% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Bluebird Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Financial statements withdrawn 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 12 · Agreement ended 1 · New debt 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Restructuring | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Financial statements withdrawnResults announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debtBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 2, 2025
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Bluebird Bio, Inc.#
$120 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid and health issues.
- Medicare/Medicaid2 reports
- Health Issues2 reports
Lobbying firms hired in 2025
Arnold & Porter Kaye Scholer LLP $120 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $120 K | — | 2 |
| 2024 | $420 K | $300 K | 6 |
| 2023 | $370 K | $370 K | 7 |
| 2022 | $120 K | $120 K | 6 |
| 2021 | $580 K | $440 K | 14 |
| 2020 | $780 K | $780 K | 20 |
| 2019 | $600 K | $420 K | 14 |
| 2018 | $290 K | — | 8 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “bluebird bio”, “bluebird bio, Inc.” and “Bluebird Bio”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Bluebird Bio, Inc.#
3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $170 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Pharmacovigilance-Medical AffairsRegulatory Affairs Specialists | 1 | $170 K |
| Director, Translational BiomarkersMolecular and Cellular Biologists | 1 | $205 K |
| Senior ScientistMolecular and Cellular Biologists | 1 | $144 K |
Where: Somerville, MA 3
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 3 | 3 | $170 K | 3 |
| FY2025 | 4 | 4 | $137 K | 4 |
| FY2024 | 9 | 9 | $165 K | 9 |
| FY2023 | 15 | 15 | $110 K | 16 |
| FY2022 | 24 | 24 | $131 K | 27 |
| FY2021 | 37 | 52 | $120 K | 41 |
| FY2020 | 39 | 61 | $125 K | 43 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as BLUEBIRD BIO, INC.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 25% of workforce | Restructuring planSEC 8-K | “The Restructuring includes a reduction of the Company’s workforce by approximately 25% of its headcount.” | Filing | |
| 30% of workforce | Restructuring planSEC 8-K | “As part of the restructuring, bluebird plans to reduce its workforce by approximately 30% across the second and third quarters of 2022.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Bluebird Bio, Inc. compares in Biotechnology
- Revenue$84 M · higher than 67% of 647
- Net margin-192.4% · higher than 29% of 408
- Revenue growth184.1% · higher than 89% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Bluebird Bio, Inc.🇺🇸 | $279 M | — | -192.4% | +184.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Employees:
- As on 2021
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, Wikidata, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Bluebird Bio, Inc.? Verify and update this profile — free
Show Bluebird Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.